Huang Tao, Zhao Ling, Lin Cheng-Yuan, Lu Lin, Ning Zi-Wan, Hu Dong-Dong, Zhong Linda L D, Yang Zhi-Jun, Bian Zhao-Xiang
Institute of Brain and Gut Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong.
YMU-HKBU Joint Laboratory of Traditional Natural Medicine, Yunnan Minzu University, Kunming, China.
Front Pharmacol. 2020 Jan 23;10:1570. doi: 10.3389/fphar.2019.01570. eCollection 2019.
In a prospective, randomized, three-arms, controlled clinical study, Chinese Herbal Medicine MaZiRenWan (MZRW, also known as Hemp Seed Pill) demonstrates comparable efficacy with Senna for functional constipation (FC) during an 8-week treatment period. Both MZRW and Senna are better than a placebo; relative to Senna and a placebo, MZRW displayed a more sustained effect during the 8-week follow-up period. The characteristic pharmacological mechanism responsible for this observation is still unclear. To explore this, we collected pre- and post-treatment serum samples of 85 FC patients from MZRW/Senna/placebo treatment groups for pharmacometabolomic analysis. An ultrahigh-performance liquid chromatography-mass spectrometer (UPLC-MS) was used for metabolic profiling and quantification. studies were conducted in constipated C57BL/6J mice to verify the effects and corresponding mechanism(s) of the action of MZRW. Pearson correlation analysis, paired t-test, one-way ANOVA analysis, χ2 test, and Student t-test were used to interpret the clinical and preclinical data. Changes in levels of circulating oleamide and its derivatives negatively correlate with improvement in complete spontaneous bowel movement (CSBM) in the MZRW group (Pearson r = -0.59, = 0.00057). The same did not hold true for either Senna or placebo groups. Oleamide is a known regulator of intestinal motility. MZRW treatment resulted in reduced levels of circulating oleamide in FC patients. Experimental verification showed that MZRW attenuated oleamide-induced slow intestinal motility in mice. MZRW decreased oleamide levels in serum, ileum, and colon in normal mice, but increased expression of colonic fatty acid amide hydrolase (FAAH). In conclusion, MZRW improved bowel movement in FC by down-regulating oleamide, possibly by enhancing FAAH-mediated degradation. Our findings suggest a novel therapeutic strategy for FC.
在一项前瞻性、随机、三臂、对照临床研究中,中药麻子仁丸(MZRW,也称为麻仁丸)在为期8周的治疗期内,对功能性便秘(FC)显示出与番泻叶相当的疗效。MZRW和番泻叶均优于安慰剂;相对于番泻叶和安慰剂,MZRW在8周的随访期内显示出更持久的效果。导致这一观察结果的特征性药理机制仍不清楚。为了探究这一点,我们收集了来自MZRW/番泻叶/安慰剂治疗组的85例FC患者治疗前后的血清样本进行药物代谢组学分析。使用超高效液相色谱-质谱仪(UPLC-MS)进行代谢谱分析和定量。在便秘的C57BL/6J小鼠中进行研究,以验证MZRW的作用效果及相应机制。采用Pearson相关分析、配对t检验、单因素方差分析、χ2检验和Student t检验来解释临床和临床前数据。MZRW组循环中油酰胺及其衍生物水平的变化与完全自主排便(CSBM)的改善呈负相关(Pearson r = -0.59,P = 0.00057)。番泻叶组和安慰剂组则不然。油酰胺是一种已知的肠道运动调节剂。MZRW治疗可降低FC患者循环中油酰胺的水平。实验验证表明,MZRW可减轻油酰胺诱导的小鼠肠道运动减慢。MZRW可降低正常小鼠血清、回肠和结肠中的油酰胺水平,但可增加结肠脂肪酸酰胺水解酶(FAAH)的表达。总之,MZRW可能通过增强FAAH介导的降解来下调油酰胺,从而改善FC患者的排便。我们的研究结果为FC提出了一种新的治疗策略。